Oncology Database

Selected news for the healthcare topic - Oncology Database, collected since 4/2019. Recent stories appear in hematologyadvisor.com and malvern-online.com. This healthcare topic shares news with Infectious Disease and Diagnostic Tests.

Please provide a valid email address.
Shares Healthcare News With (link):
Healthcare Topics

Selected Headlines

Date Headline (link) Source Relevant Snippet
3/2/2021 Nivolumab Effective for Advanced NSCLC in Real-World Practice journalofclinicalpathways.com ... Pharmaceutical Sciences, University of Minnesota, Duluth, and colleagues.This study aimed to evaluate the effectiveness of nivolumab in patients with advanced NSCLC receiving treatment at community hospitals in the United States.The Flatiron Health oncology database was used to extract patient data from electronic health records. OS was evaluated in patients receiving nivolumab for advanced NSCLC after prior chemotherapy.Subgroup analyses were performed by baseline characteristics included Eastern Cooperative Oncology ...
1/20/2021 Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries blogspot.com ... ArticleToolsShareAbstractBackground: Advances in therapies for patients with metastatic colorectal cancer (mCRC) and improved understanding of prognostic and predictive factors have impacted treatment decisions. Materials & methods: This study used a large oncology database to investigate patterns of monoclonal antibody (mAb) plus chemotherapy treatment in France, Germany, Italy, Spain and the UK in mCRC patients treated in first line in 2018. Results: Anti-EGFR mAbs were most often ...
1/20/2021 Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries blogspot.com ... 2020-0976 Sections Share Abstract Background: Advances in therapies for patients with metastatic colorectal cancer (mCRC) and improved understanding of prognostic and predictive factors have impacted treatment decisions. Materials & methods: This study used a large oncology database to investigate patterns of monoclonal antibody (mAb) plus chemotherapy treatment in France, Germany, Italy, Spain and the UK in mCRC patients treated in first line in 2018. Results: Anti-EGFR mAbs were most often ...
1/20/2021 Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries blogspot.com ... ArticleToolsShareAbstractBackground: Advances in therapies for patients with metastatic colorectal cancer (mCRC) and improved understanding of prognostic and predictive factors have impacted treatment decisions. Materials & methods: This study used a large oncology database to investigate patterns of monoclonal antibody (mAb) plus chemotherapy treatment in France, Germany, Italy, Spain and the UK in mCRC patients treated in first line in 2018. Results: Anti-EGFR mAbs were most often ...
1/20/2021 Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries blogspot.com ... ArticleToolsShareAbstractBackground: Advances in therapies for patients with metastatic colorectal cancer (mCRC) and improved understanding of prognostic and predictive factors have impacted treatment decisions. Materials & methods: This study used a large oncology database to investigate patterns of monoclonal antibody (mAb) plus chemotherapy treatment in France, Germany, Italy, Spain and the UK in mCRC patients treated in first line in 2018. Results: Anti-EGFR mAbs were most often ...
1/20/2021 Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries blogspot.com ... ArticleToolsShareAbstractBackground: Advances in therapies for patients with metastatic colorectal cancer (mCRC) and improved understanding of prognostic and predictive factors have impacted treatment decisions. Materials & methods: This study used a large oncology database to investigate patterns of monoclonal antibody (mAb) plus chemotherapy treatment in France, Germany, Italy, Spain and the UK in mCRC patients treated in first line in 2018. Results: Anti-EGFR mAbs were most often ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... tel : 00302841026182,00306932607174 Πληροφορίες Προβολή πλήρους προφίλ Τρίτη, 19 Ιανουαρίου 2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database Cancer shared this article with you from Inoreader Message: Background: The literature on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
1/20/2021 Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database blogspot.com ... on biomarker testing for metastatic colorectal cancer (mCRC) in Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five European countries tested for biomarkers over time. Materials & methods: An oncology database was retrospectively analyzed; evaluated biomarkers were RAS, BRAF and microsatellite instability (MSI). The patients were drug treated during 2018 and tested for relevant biomarkers in 2013–2018. Results:RAS testing was conducted in 90 ...
10/22/2020 Modern Radiation Therapy Limits Radiation Doses to Organs at Risk in Hodgkin Lymphoma hematologyadvisor.com ... to determine the radiation doses delivered to organs at risk with consolidative modern involved-site RT in patients with ESFHL treated with 20 Gy after 2 cycles of ABVD.The investigators screened the radiation oncology database maintained by the University of Texas MD Anderson Cancer Center for medical records of adult patients with ESFHL (German Hodgkin Study Group criteria) who had been treated with combined modality therapy from 2010 to ...
9/17/2020 malvern-online.com ... the Emmes SARS-CoV-2 Testing Database. This database serves as the latest addition to the market intelligence products already under DeciBio Consulting’s umbrella. Such products include the Emmes Infectious Disease Database, the Emmes Oncology Database , BioMAP (immuno-oncology biomarkers), Marketbooks, Dexter, and BioTrack, among others. The DeciBio Emmes SARS-CoV-2 Testing Database provides data visualization tools and raw data covering coronavirus testing practices in approximately 400 labs in ...
4/17/2020 Optimizing the Analytical Value of Oncology-Related Data Based on an In-Memory Analysis Layer: Development and Assessment of the Munich Online Comprehensive Cancer Analysis Platform jmir.org ... patients themselves, their medical history, and tumor descriptives. The software is suitable for not only a specific tumor site but also for all solid and nonsolid tumors, resulting in a large, complex, and comprehensive oncology database . The software was established at the local sites in 2010 and now includes most tumor entities. By the end of 2018, the databases contained detailed information for more than 20,000 patients at each site ...